Evaluation of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunizations in Patients with B-Cell Malignancies

Background Multiple vaccines have been granted emergency use authorization by the Food and Drug Administration against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of the currently available vaccines, none have been systematically studied for efficacy or toxicity in patients with im...

Descripción completa

Detalles Bibliográficos
Autores principales: Singal, Mukul, Kalvehalli Kashinath, Sanjana, Mustafa, S Shahzad, Walsh, Edward, Vadamalai, Karthik, Jamshed, Saad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701608/
http://dx.doi.org/10.1182/blood-2021-153420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701608/
http://dx.doi.org/10.1182/blood-2021-153420

Ejemplares similares